Hemopoietic stem cells from human fetal liver were transplanted in utero into preimmune fetal sheep (48-54 days of gestation). The fate of donor cells was followed using karyotype analysis, by immunofluorescence labeling with anti-CD antibodies, and by fluorescent in situ hybridization using human-specific DNA probes. Engraftment occurred in 13 of 33 recipients. Of five live born sheep that exhibited chimerism, all expressed human cells in the marrow, whereas three expressed them in blood as well. Engraftment was multilineage (erythroid, myeloid, and lymphoid) and human hemopoietic progenitors (multipotent colonyforming units, colony-forming units-granulocyte, macrophage, and erythroid burst-forming units) capable of forming colonies in vitro were detected in all five lambs for greater than 2 yr. These progenitors responded to human-specific growth factors both in vitro and in vivo. Thus the administration of recombinant human IL-3 and granulocyte macrophage-colonystimulating factor to chimeric sheep resulted in a 2.1-3.4-fold increase in the relative expression of donor (human) cells. These results demonstrate that the permissive environment of the preimmune fetal sheep provides suitable conditions for the engraftment and long-term multilineage expression of human hemopoietic stem cells in a large animal model. In this model, donor human cells appear to retain certain phenotypic and functional characteristics that can be used to manipulate the size of donor cell pool.
and animals is achieved when the host and graft are immunologically tolerant of each other and/or when the immunological barmer is inoperative (1, 2) . Tolerance oftransplanted allogeneic cells in clinical settings can be achieved using genetically immunodeficient donors/recipients (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Alternatively, immunocompetent recipients can be rendered immunotolerant by using immunosuppressive and/or cytoablative procedures, which may also serve to promote engraftment by donor HSC by eliminating recipient HSC which may compete for homing sites within the bone marrow (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . HLA matching and T cell depletion ofthe donor graft are also useful adjuncts to mitigate development of life-threatening graft versus host disease (GVHD) which may occur during graft rejection (1, 2) . When applied appropriately, these procedures have been used to achieve chimerism between different species including humanmouse (4) (5) (6) (7) (8) (9) (10) . Xenogeneic transplantation ofhuman HSC has also been reported in genetically deficient mice (5) (6) (7) (8) (9) (10) and in normal mice rendered tolerant by lethal irradiation (4) .
A radically different approach to overcome the immune barrier which is operative in hemopoietic cell transplantation is the use ofpreimmune fetal systems. This approach exploits the fact that during the first and second trimester, recipient fetuses are immunologically "naive" and incapable of mounting a reaction to reject the donor cells, while the preimmune donor cells are also equally incapable of inducing GVHD (3, 11, 12) . In addition, expansion of the fetal marrow compartment and normal intertissue HSC migration patterns during fetal development may contribute to the receptivity ofthe marrow environment to transplanted donor cells (see Discussion). Donor HSC transplanted at appropriate gestational ages in utero may home to a relatively "empty" marrow, thus facilitating the establishment ofdonor hemopoiesis before the seeding ofendogenous HSC. Thus, the fetal environment may provide unique opportunities to achieve long-term donor hemopoiesis without the requirement of cytoreduction and immune suppression (3, (12) (13) (14) .
We have previously described successful transplantation of allogeneic HSC in utero in sheep and monkeys (12) (13) (14) . Fetal liver-derived sheep HSC transplanted into unrelated preimmune fetal recipients contributed to long-term hemopoietic chimerism for several months afterbirth (12, 13) without development of GVHD. Hemopoietic chimerism was stable and donor stem cells produced erythroid, myeloid, and lymphoid progeny (3, (12) (13) (14) , suggesting that the early gestational age fetuses provide both the ideal donor and recipient environments to achieve HSC engraftment without resorting to cytoablative or immunosuppressive procedures.
Successful long-term establishment ofxenogeneic chimeras provides the ultimate test of the basic concept of using preimmune donors and recipients to circumvent the immunological barrier thereby inducing tolerance to foreign cells. We describe here the engraftment and proliferation of human fetal HSC transplanted in utero into a large animal model. We used cyto-genetic and culture techniques, DNA-based detection strategies, and flow cytometric analysis of phenotypic markers to detect and monitor the expression of human HSC in recipient sheep. We demonstrate that the permissive environment ofthe preimmune sheep allows engraftment and long-term (> 2 yr) multilineage expression of human HSC.
Methods
Donor cell preparation and transplantation procedures. The studies were conducted in fetal sheep at 48-54 d of gestation (term: 145 d). Dorset Merino ewes (Ovis aries) with confirmed dates of conception were purchased from local suppliers and acclimatized for 10 days before donor cell infusion into the fetus. The microbubble technique used for the in utero transplantation ofdonor cells has been described previously (I13). Briefly, after a 48-h fasting period, maternal ewes were sedated with ketamine (10 mg/kg, intramuscularly), and received 0.5-1.0% halothane-oxygen mixture by inhalation via an endotracheal tube. The external jugular vein was cannulated for administration of fluids and antibiotics (penicillin, 2 million U; kanamycin, 400 mg). The uterus was exposed through a midline incision, and the myometrial layers were divided with electrocautery, leaving the amnion intact. The fetus was manipulated within the amniotic sac and, under direct visualization, donor cells (2 X I09 -1 X 100' cells/kg estimated fetal body wt in 0.5-1.0 ml) were injected into fetal peritoneal cavity. Uterine and maternal body walls were closed in layers and the ewes, after full recovery, were provided food and water ad lib.
Donor cells were derived from livers of 12-15- (15) . A single cell suspension of mononuclear cells was prepared in the same medium by gentle homogenization of tissue fragments in a handoperated glass homogenizer (Broeck Tissue Grinder; Fisher Scientific Co., Pittsburgh, PA). The cell mixture was centrifuged (450 g, 8 min) and the pellet resuspended (2 X I0' cells/ml) in the same medium and incubated at 37°C, 5% CO2 in humidified air for 12-17.5 h. After incubation, the cell suspension was centrifuged once again and the cells resuspended in the same medium at desired concentrations of 4-20 X I07 cells/ml for injection.
Assessment ofdonor cell engraftment. The presence ofdonor cells in hemopoietic tissues of the recipients was sequentially determined at intervals posttransplantation using karyotypic analyses of blood, marrow, and liver hemopoietic cells before and after in vitro cultures, by using flow cytometric analysis of differentiation antigens associated with human hemopoietic subpopulations, and by using fluorescence in situ hybridization (FISH) with DNA probes specific for repeated satellite sequences on human autosomes. Donor cell engraftment was assessed both before and after birth. Mononuclear cells were obtained by standard procedures (homogenization, flushing of long bones, density gradient separation) from liver, bone marrow, and blood of five recipients at 2 wk after transplantation and from two recipient fetuses each at 4, 6, and 8 wk after donor cell infusion. Blood and marrow hemopoietic mononuclear cells were obtained for analysis from 22 other surviving recipients at 1-2 wk after birth and at about monthly intervals thereafter.
Karyotypic analysis. Karyotypic analyses were used to establish donor cell engraftment in all recipients examined before birth and in all surviving lambs for -1 yr after transplantation. All samples were analyzed for lymphoid elements expressing human karyotype after stimulation with PHA in the presence of appropriate controls as described (14) . (14, 16) . All cultures were established in IMDM with erythropoietin (2 IU/ml recombinant human erythropoietin [rHuEpo] ). For optimal growth of sheep CFUMix, CFU-GM, and BFU-E, the cultures were supplemented (5% vol/ vol) with a preparation of PHA-stimulated leukocyte-conditioned medium (sheep PHA-LCM) produced with a mixture offetal sheep spleen, thymus, liver, and bone marrow cells in IMDM with 2% fetal sheep serum (14) . Optimal growth of human hemopoietic progenitors was achieved with the addition of5 ng/ml each ofrecombinant human IL-3 (rHuIL-3) and GM-CSF to cultures in the absence ofPHA-LCM. Colonies were enumerated and processed for karyotyping on days 9, 14, and 19 of incubation (370C, 5% CO2 in humidified air).
The methylcellulose culture procedure was also used to establish the relative efficacy of sheep PHA-LCM and/or rHuIL-3/GM-CSF in promoting the growth and development of sheep or human hemopoietic progenitors in vitro. Light density mononuclear cells isolated from adult sheep or human bone marrow aspirates by Ficoll-Hypaque separation (16) were cultured (0.5-1 x 105 cells/ml) with Epo (2 IU/ml) and varying concentrations ofeither sheep PHA-LCM (0.5-20% vol/vol) or rHuIL-3/GM-CSF 1-20 ng/ml) as described (16) . Colonies were enumerated at 48-h intervals beginning at day 5 ofincubation until day 19 of culture.
Karyotypic analysis ofhemopoietic colonies. Colonies were identified by type (16) , removed from the plates individually, placed in buffered normal saline colcemid solution, mixed, and incubated at 37°C for 30 min. The mixture was then centrifuged at 200 g for 8 min, the supernate was removed, and the cell pellet was slowly resuspended in a solution of prewarmed (37°C) potassium chloride. The mixture was incubated at 37°C for 10 min, spun at 200 g for 8 min, and the cell pellet resuspended. A fixative solution of 33% glacial acetic acid inmethanol was slowly added to the cell suspension and the cells processed for karyotype analysis as described (14) .
Immunofluorescence labeling andflow cytometric analysis. Blood and marrow were processed for immunofluorescence labeling and flow cytometric analysis. Leukocytes were isolated from whole blood by hypotonic lysis of erythrocytes. Whole blood collected in EDTA was added to 15 vol of lysis buffer (I170 mM NH4Cl, 0.1 mM EDTA, 1 mM KHCO3, at pH 7.3). Samples were incubated at room temperature for 4-5 min while inverting every 30 s. Cells were pelleted (all centrifugations were for 5 min at 300 g) and the lysis was repeated as necessary until the pellet was relatively free of erythrocytes. Bone marrow was processed in a similar manner to remove contaminating red cells. Isolated blood leukocytes and whole bone marrow were washed once in cold S-Hank's balanced salt solution containing 0.02% sodium azide.
Aliquots of 5 X I05 cells were then resuspended in 100 ul cold S-HBSS for staining with CD antibody reagents. Whole blood was fixed with formalin as described previously (17) (17, 18) . Fluorescently labeled nucleated cells were analyzed with a dual laser flow cytometer (FACStarx Plus, Becton Dickinson, Mountain View, CA). Stained cells were excited with argon lasers adjusted to emit in the UV region and at 488 nm. Signal acquisition was triggered on Hoechst fluorescence collected through a 458-band pass filter. The antibody-linked fluorophores, FITC and phycoerythrin, were excited at 488 nm and fluorescence emission collected through 514-and 585-nm band pass filters, respectively. Flow cytometric analysis oferythrocytes was performed on a FACScan" flow cytometer using C30 software as described previously (17 during the remainder of gestation and after birth. Of the 42 fetuses who received human cells, 9 were lost to the study due to surgery, 11 were sacrificed before birth for sequential studies, and 22 were allowed to complete gestation and were born alive. Engraftment of human cells was documented in eight recipients who were sacrificed before birth and in five who were born alive. Thus, of the 33 fetuses who could be studied either before or after birth, chimerism could be documented in 13 (40%). No evidence of GVHD was noted in these animals. The criteria for GVHD were wool loss, diarrhea, and histological evidence of GVHD in lip biopsy. Our protocols also called for skin and liver biopsies when questions existed.
Donor (human) cell engraftment in all recipients sacrificed before birth was determined by karyotypic analysis of blood and other hemopoietic tissues. Karyotyping was also the primary procedure used to establish and monitor the presence of human cells in all recipients after birth. Flow cytometry and FISH were used to confirm and provide further detailed evaluation of donor cell engraftment in the stable chimeric lambs at around one year after birth (15 months after transplantation).
Donor cell engraftment by karyotypic analysis was assessed at two levels. Analysis of metaphases after routine stimulation of peripheral blood and marrow aspirations provided evidence of lymphoid engraftment. Engraftment of donor erythroid and other myeloid cells, however, required karyotypingofhemopoietic colonies formed in cultures of mononuclear cells obtained from liver/spleen and bone marrow of recipients before birth and from bone marrow of transplanted lambs after birth.
In preliminary studies, the effect ofdifferent concentrations of sheep PHA-LCM or rHuIL-3 and GM-CSF on colony formation by normal human and sheep hemopoietic mononuclear cells in vitro was determined. Under conditions used here, optimal growth of sheep CFU-Mix, BFU-E, and CFU-GM-derived colonies occurred only when adequate concentrations of sheep PHA-LCM, usually 4-7% (vol/vol), were present. Maximal numbers of colonies were detected by day 9 of incubation. Thereafter, both the number and size of colonies decreased. Few colonies were still present on day 12, but none were observed after 15 days ofculture. In these studies, optimal development ofhuman CFU-Mix, BFU-E, and CFU-GM were found to occur in the presence of 5 ng/ml ofIL-3 and GM-CSF. Maximal numbers of colonies were present at about 13-15 days ofincubation. About 67-84% ofcolonies were still present at day 19. Similar results were obtained when artificially created mixtures of human and sheep bone marrow mononuclear cells were cultured in the presence of sheep PHA-LCM (5% vol/vol) and/or 5 ng/ml each ofrHuIL-3 and GM-CSF. Karyotypic analysis of individual colonies of different types (CFUMix, BFU-E, CFU-GM) grown in mixtures composed of 3-25% human cells revealed the presence of predominantly (92±12%; n 10) sheep colonies at day 9, mostly (73±14%; n = 10) human colonies on day 14, and almost exclusively (98±24%; n = 10) human colonies on day 19 of incubation.
In general, as shown in Figs. 1 and 2, concentrations of sheep PHA-LCM (4-7%) and rHuIL-3/GM-CSF (5 ng/ml) shown to promote the optimal development of sheep and human colonies in vitro, respectively, had only minimal effect on cells of the other species. At higher concentrations (> 20 ng/ ml) human cytokines stimulated the formation of some sheep colonies in vitro (data not shown). However, we were not able to achieve optimal growth of sheep colonies in the presence of human cytokines at any concentration (5-100 ng/ml). Because oftoxicity we were unable to test the effect ofhigher concentra- tions ofsheep PHA-LCM (>10% vol/vol) on human hemopoietic progenitors in vitro. However, at nearly all concentrations tested, sheep PHA-LCM exerted some, albeit statistically insignificant, stimulatory effect on human colony development in vitro. This was most evident with CFU-Mix-derived colonies, a few ofwhich formed in the presence ofsheep PHA-LCM (Fig.  1) . The effect ofsheep PHA-LCM on human BFU-E was manifested by a noticeable increase in the size of these colonies; no effect on CFU-GM was detected.
Therefore, all karyotypic analyses ofprogenitor-derived colonies presented here were obtained by culturing the cells in the presence of 5% vol/vol sheep PHA-LCM and/or 5 ng/ml each of rHuIL-3 and GM-CSF. Colonies were enumerated and karyotyped on days 9 and 19 of culture for sheep and human colonies, respectively. These values were used to calculate the percentage of colonies with human karyotypes.
Results summarized in Fig. 3 demonstrate that bone marrow and liver in 8 of 11 fetal recipients sacrificed before birth contained human cells. Human hematopoietic progenitors (CFU-Mix, BFU-E, CFU-GM) comprised about 9% ofthe total committed progenitor pool in bone marrow at two weeks after transplantation. The proportion of human cells in bone marrow gradually decreased to 4% over the next six weeks. Liver contained significantly fewer (P < 0.01) donor progenitors at two weeks; no human cells were present in host liver at eight weeks after transplantation. Human cells were not present in the peripheral blood of the sheep fetuses at any time.
All 22 live born lambs were evaluated for the presence of human cells by karyotyping at about two weeks after birth. Five newborn sheep exhibited human cell chimerism. Of these, two lambs expressed human cells in bone marrow only (Table II) and three had human cells in both bone marrow and peripheral blood, with levels ranging from 0.4 to 3.8% (Table II) . The results presented in Table II were obtained by analysis ofmetaphases obtained after routine PHA stimulation, and as such reflect the relative percentages of human lymphoid cells present in blood and bone marrow of these lambs at this time.
The relative distribution of human erythroid and myeloid progenitors in bone marrow of the five chimeric sheep at two weeks is presented in Table III . Significant numbers of human progenitor-derived colonies were detected in all five lambs. It is interesting to note that the mean ± 1 SEM ofall three progenitor types for all five lambs is 5.2±1.11%, a value that is similar to the value obtained for the eight chimeric fetal recipients at eight weeks after transplantation (Fig. 3) indicating a possible stabilization of donor cell engraftment in these animals. The multilineage nature ofhuman cell engraftment in chimeric animals was also demonstrated by flow cytometry and FISH. (17) . The results, illustrated in Fig.  4 , a-c, confirmed that both animals contained subpopulations ofGPA-positive cells. The data generated in Fig. 4 a were from an artificial mixture of human (15%) and sheep (85%). It may appear visually that the frequency of human cells in this mixture is greater than 15%. In reality, however, the majority of human erythrocytes have zero fluorescence intensity and thus lie directly on the y and x axis. No gates were used for display of data in Fig. 4 CD 16 , which appeared to label a minor subpopulation in control sheep marrow. In all cases, nucleated subpopulations in chimeric sheep tissues that were labeled with the CD-associated antibodies were sorted onto slides, and the actual frequency of human cells in the sorted population was quantitated after fluorescence in situ hybridization (19, 20) with biotinylated DNA probes specific for human repeated centromeric sequences (20, 21) . The purity of the sorted immunofluorescence-positive subpopulations ranged between 45 and 93% (see Table IV legend for details). Data shown in Table IV Figure 4 . Flow cytometric analysis of sheep blood samples labeled with monoclonal antibodies specific for the human MN blood group antigens on erythrocytes. Blood cells were fixed with formaldehyde and labeled with two fluorescently tagged monoclonal antibodies. The antibody 6A7 labels the M-form of human GPA, while the antibody BRIC157 labels the N-form of GPA. The details of the fixation, labeling, and flow cytometry have been described previously (17, 18 pressor (CD8). Human cells present at a frequency of0.1% can be detected by flow cytometric analysis of immunofluorescently labeled subpopulations (20) . Thus, these data suggest that CD8-positive cells may not be involved in maintenance of tolerance in chimeric sheep, although this is by no means established. The relative fraction of individual human subpopulations in sheep marrow and blood was compared with the distribution of similar subpopulations in human marrow and blood. Human marrow and blood was stained with the identical antibody panel used in the analysis of the chimeric sheep samples. All data were normalized to the fraction of the subpopulation which expressed CD45, a marker of all human leukocytes and lymphocytes with the exception of nucleated erythroid cells (Table IV) . The CD34 fraction of marrow in chimeric sheep was three-to fourfold higher than in normal marrow. In blood of sheep 3419, CD34-positive cells comprised a remarkably high fraction (46%) of the engrafted leukocytes. In contrast, human blood contained only 0.3% CD34-positive cells. Similarly, the frequency of CD4-positive cells in chimeric sheep is higher than found in human blood. The frequency of other chimeric marrow subpopulations is within a two-to fourfold range of similarly defined subpopulations in human marrow.
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Thus, flow cytometric analysis and sorting ofimmunofluorescently labeled cells followed by FISH with human-specific DNA probes demonstrated that xenogeneic chimerism was achieved in three ofthe major hemopoietic lineages. Both mature and immature human cells were present, suggesting that the chimeric lineages contained a large complement of differentiated cells. Although the distribution ofindividual subpopulations within the engrafted hemopoietic system was not identical to that seen in normal human marrow and blood, the GPA erythrocyte data and the leukocyte cell surface markers suggested that the phenotypic and size characteristics resemble those of normal human cells.
Results presented in Fig. 6 show that, despite generally decreasing relative frequencies, donor cells continue to be present in bone marrow ofall five, and blood oftwo chimeric lambs for up to two years after transplantation. Sheep 3425, which at birth had exhibited donor cells in both marrow and blood, no longer shows human cells in the blood. Peripheral blood samples obtained from this animal beginning at 15 months after transplantation failed to show cells with human karyotype (Fig.  6) . It is interesting to note that unlike the other four lambs which continue to exhibit all three human hemopoietic progenitor types (CFU-Mix, CFU-GM, BFU-E) in bone marrow, marrow from sheep 3425 develops only CFU-GM-derived colonies in vitro.
Effect ofrHuIL-3 and GM-CSF on donor cell expression in chimeric lambs. The relative refractoriness ofsheep hematopoietic progenitors to human IL-3 and GM-CSF is apparent from the data presented in Table V . With no additions to culture, modest numbers of myeloid and erythroid colonies were observed on day nine. These colonies were no longer present by day 19 . This is characteristic of colonies formed by sheep bone marrow but not by human cells in this assay. However, when human-specific growth factors were added to the culture, while the colony counts were little changed on day 9 compared to control, numerous colonies were present on day 19, suggesting the presence of viable human colony forming units. This was confirmed by karyotype analysis on day 19: all but one erythroid colony found on this day were composed entirely of human cells (Table V) .
To assess whether this functional response could also be elicited in vivo in chimeric animals, we injected the long-term chimeric animals 3419, 3425, and 3425C with rHuIL-3 and GM-CSF at 8 ,ug/kg twice daily for four days intravenously, Months After Transplantation Figure 6 . (4) (5) (6) (7) (8) (9) (10) . Both irradiated mice (4) and genetically immunodeficient mice (5-10) have served as recipients. Initially, the reconstitution of lymphoid lineages was noted and the expression was ofrather transient nature (5, 7) . Reconstitution for at least six months was also reported by Mosier et al. (6) and by Namikawa et al. (10) who observed reconstitution of human multilineage hemopoiesis in mice lasting for a period of 5-1 1 months.
Functional potential of engrafted cells has been documented in most studies (8) . Transfer of autoimmune disease has been accomplished by the transfer of lymphocytes from patients with primary biliary cirrhosis into severe combined immunodeficient mice (8) . Human antibody response to dinitrophenol has been observed by Lubin et al. (4) after primary and secondary immunization (4) .
Generally, immunodeficient mice have been the preferred recipients for engraftment of human HSC. This is due to the fact that irradiated mice retain some natural killer cells and lymphocyte-activated killer cells that form a barrier to the growth ofhuman cells (23, 24) . On the other hand, immunodeficient mice poorly engraft or differentiate into T cells unless thymic epithelium is also implanted under the kidney capsule (5, 10) . In this regard, preimmune fetuses can overcome both of these barriers.
The feasibility of this xenograft system is derived from the fact that both donors and recipients are immunologically naive and exceptionally tolerant of each other. Donor cells are derived from 12-15-week-old human fetuses, whereas the immunological system in humans develops between 12 and 20 weeks of gestation (1 1, 25) . Thus, the possibility of donor cells reacting against the recipient animal in a GVH type of reaction is minimized. On the other hand, the recipients, being less than eight-week-old fetuses, are also preimmune (26) and incapable ofgraft rejection that would otherwise be expected. In this context the use of xenogeneic grafting is particularly desirable, since, in general, the immune response to xenograft is weaker than that of allogeneic response (27) .
The possibility of making preimmune fetuses tolerant of otherwise immunologically incompatible cells has been evident since the work of Owen in 1945 (28) who anastomosed placentae of bovine dizygotic twins. This led to long-term retention of red cells ofdizygotic origin in both twins. Parabiosis in chick embryos (29) and other works (30, 31) subsequently confirmed this experiment. Billingham et al. (32) , in a classic work, were then able to actively induce acquired tolerance in mice by in utero introduction of unrelated cells. Similar observations have been subsequently reported by others, including our own groups in other species in both allogeneic and xenogeneic systems (4-10, 12-14, 26, 33) . The frame ofreference is thus both long-standing and wide. In a postnatal setting, tolerance is generally induced by conditioning regimens such as ionizing radiations and/or cytoablative therapy (1, 2) . This treatment not only overcomes the immunological barrier, but also depletes the endogenous stem cell pool and permits ready expansion of donor HSC pool which can now occur without competition (1, 2) . By contrast, HSC engraftment in the fetus occurs without the need for conditioning regimens (12) (13) (14) .
In addition to immunological tolerance afforded by the preimmune status of the fetus, fetal transplantation offers a unique setting for engraftment of exogenous sources of HSC. The uniqueness is derived from the predictable switch in the sites of hemopoiesis during ontogeny. During the embryonic and fetal life, hemopoiesis moves consecutively from yolk sac to liver/spleen and then to the bone marrow (reviewed in references [34] [35] [36] [37] . With the exception of the early embryonic period when the yolk sac is hemopoietic, during most of the fetal life hemopoiesis is a function of liver/spleen. During the latter part of gestation, bone, and consequently, marrow, spaces begin to develop and expand. HSC then migrate from liver/ spleen to the marrow in a steady, continuous fashion. They occupy hemopoietic sites or "niches" in the developing marrow which is now ready to accommodate their homing and proliferation (38) . During this period when an exogenous source of HSC is introduced in the fetus, particularly in a large dose (single or multiple), these cells can effectively compete with those of the endogenous sources for homing and engraftment to the marrow (39) . However, unless the transplanted HSC are introduced in a continuous, steady fashion, competing native HSC may gain a competitive edge. This may explain our observation that in certain cases the relative proportion of cells with human markers is subsequently reduced in the marrow even though the total pool of these human cells may expand with the growth of marrow cavities. Repeated transplantation of exogenous HSC over a period oftime may regain the competitive edge for these cells.
Our data presented here are consistent with the view that although during the latter part of gestation, marrow hemopoietic sites expand and are primed to receive migrating HSC (exogenous or endogenous), the contribution of marrow to the formation of circulating blood cells is negligible, if any. This is evident from the observation that no circulating cells with human markers were noted during this period, despite their presence in the bone marrow. Cells with human markers appear in the blood only during the perinatal period when liver ceases to be hemopoietic and bone marrow assumes this function. In the interim, engrafted HSC may remain in the marrow and undergo proliferation without significant differentiation. This can only lead to the expansion of HSC pools (both exogenous and endogenous) parallel to the expansion of marrow cavities (34) (35) (36) .
Certain maneuvers may provide the donor HSC pool with a competitive edge, thus enhancing the success in transplantation. The dose of given HSC may be one such factor. In the present work, this could not be well-controlled for, because of the use of aborted human fetuses. However, studies using allogeneic fetal transplantation in sheep and monkeys (12) suggest a dose-dependence in engraftment success. Increasing the cell dose may then provide a higher proportion of cells engrafted.
In this regard, fractionation and concentration ofHSC in vitro, before infusion, may also be helpful.
Another factor could be the optimal time and dose schedule during the gestation period when homing of donor cells could be maximized relative to the intrinsic pool of HSC. This requires an extended time course study with well-controlled doses of transplanted cells.
Another maneuver, addressed in the present study, is the use of species-specific growth factors. The data presented here clearly demonstrate that sheep HSC are not responsive to the concentrations of human recombinant growth factors used here. Similar species specificity has been documented for IL-3 in human and mice (40) . Such growth factors could provide donor cells with a competitive edge when used in vivo after transplantation. Thus, the pool ofdonor cells could be induced to expand by the use ofrHuIL-3 and rHuGM-CSF, irrespective of the method of detection (karyotyping, FISH, etc.). In this regard, the use of other recombinant growth factors deserves consideration, since they may provide means of manipulating the engraftment and proliferative capacity of donor cells. We have shown that in adult murine system, a briefin vivo incubation of donor cells, before transplantation, can increase the density of homing receptors on the cell surface and subsequently enhance the grafting ability ofthese cells (15) . A similar maneuver has also been successful in allogeneic transplantation in the fetal system (41) and may be worthy of consideration in xenogeneic transplantation as well. By contrast, using a pump system in immunodeficient mice, rHuGM-CSF and IL-3 did not increase the number ofengrafted macrophage colonies (7) , giving rise to the suggestion that engrafted human cells may provide their own growth factors. An alternative interpretation would be that macrophage colonies may behave differently in their response to growth factors in this setting.
Proliferation and sustenance of donor HSC require the use of humoral and cellular machinery of bone marrow stroma which is provided by the recipient. The responsiveness of donor cells to species-specific growth factors suggests that, in this xenograft system, donor cells may not fully integrate into the recipient's marrow stroma. That engraftment and cellular proliferation ofdonor cells occur at all, raises a fundamental question in HSC transplantation. It is possible that stromal cells are transplanted along with HSC and these elements can be used by donor cells to provide species-specific cellular and humoral machinery for hemopoietic cellular proliferation. There exists some evidence in the literature for stromal cell transplantability (42) . The xenograft system, described here, may offer several potential applications. First, it can serve as a technique for assaying engraftment potential of human HSC. In the mouse, transplantability can be measured by colony-forming assay in spleen (43). In the human system, however, only the number of HSC can be estimated in vitro by CFU-Mix assay. This assay may not bear a relationship to their transplantability which relates to specific cell surface receptors (44, 45 In this regard, it should be mentioned that our present data demonstrate that human cells in the host animals are capable of differentiating into lymphoid cell lines. This potential may allow them to respond to certain antigens and the production of human immunoglobulins which could subsequently be recovered from the serum by affinity techniques, using antihuman Ig antibodies. Thus, the system may be potentially a source ofproduction ofhuman immunoglobulins as well. Realization ofthese theoretical potentials all require further studies.
Finally, in utero transplantation of hemopoietic cells, per se, offers a new realm of possibilities, otherwise not attainable by the existing techniques in postnatal setting: with the availability of procedures for prenatal diagnoses of many genetic disorders, the possibility of in utero therapeutic intervention for the correction of many genetic defects can now indeed be realized by the introduction of normal HSC (46, 47) . In utero intervention precludes potential rejection and GVHD, otherwise expected in a postnatal setting.
